Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Announces Quarterly Earnings Results

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) released its quarterly earnings data on Monday. The company reported ($2.17) EPS for the quarter, topping the consensus estimate of ($408.00) by $405.83, FiscalAI reports.

Valion Bio, Inc. Common Stock Stock Down 4.2%

NASDAQ:VBIO opened at $0.18 on Tuesday. The company’s 50-day simple moving average is $0.43 and its 200-day simple moving average is $0.76. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.02 and a current ratio of 3.31. Valion Bio, Inc. Common Stock has a fifty-two week low of $0.16 and a fifty-two week high of $3.66. The stock has a market capitalization of $757,375.00, a P/E ratio of -0.03 and a beta of 1.85.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

About Valion Bio, Inc. Common Stock

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.